[Federal Register Volume 82, Number 176 (Wednesday, September 13, 2017)]
[Notices]
[Pages 43026-43027]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-19315]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Department of Health and Human 
Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Government owned intellectual property covering HIV-1 reverse 
transcriptase inhibitors available for licensing and commercialization.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by emailing the 
indicated licensing contact at the National Heart, Lung, and Blood, 
Office of Technology Transfer and Development Office of

[[Page 43027]]

Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 
20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: The inventions listed below are owned by an 
agency of the U.S. Government and are available for licensing in the 
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing. A description of the technology available for 
licensing follows.

Pyrophosphate Analog HIV-1 Reverse Transcriptase Inhibitors

    Description of Technology: The invention relates to compounds that 
inhibit HIV-1 DNA synthesis mediated by reverse transcriptase (RT). 
HIV-1 DNA synthesis by RT utilizes deoxynucleoside 5'-triphosphate 
(dNTP) as substrate and like many other enzymes, the reaction is 
reversible. Pyrophosphate analogs like imidodiphosphate strongly 
promote reverse reaction dNTP products containing the imidodiphosphate 
group instead of the naturally occurring pyrophosphate group. This 
imidodiphosphate-containing dNTP was found to be a potent inhibitor of 
the forward RT reaction. Whereas pyrophosphorolysis is limited by a 
nonchemical step, replacing the bridging oxygen of pyrophosphate with 
an imido group resulted in a change in the rate-limiting step, so that 
the imidodiphosphate-dependent reverse reaction was limited by 
chemistry. There exists, then, the potential to use pyrophosphate 
analogs therapeutically.
    Potential Commercial Applications:
     Anti-microbial.
     HIV therapeutic.
    Development Stage:
     In vitro data available.
    Inventors: Samuel Wilson, William Beard, David Dion Shock (all of 
NIEHS).
    Intellectual Property: HHS Reference No. E-210-2017/0-US-01.
     U.S. Provisional Patent Application 62/542,600 filed 
August 8, 2017.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Environmental Health Sciences seeks statements of capability or 
interest from parties interested in collaborative research to further 
develop and evaluate, please contact Sally E. Tilotta, Ph.D., Director, 
Office of Technology Transfer, National Institute of Environmental 
Health Sciences, Phone: (919) 316-4526; [email protected].

    Dated: September 7, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2017-19315 Filed 9-12-17; 8:45 am]
 BILLING CODE 4140-01-P